-
1.发明公开
公开(公告)号：EP3835787A1
公开(公告)日：2021-06-16
申请号：EP20207809.3
申请日：2017-02-16
IPC分类号： G01N33/564
摘要： The invention relates to the use of (auto)antibodies against the C-X-C chemokine receptor type 3 (CXCR3) as a prognostic marker in subjects with acute graft-versus-host disease (GVHD), particularly in subjects with high grade acute GVHD. The invention also relates to the use of C-X-C chemokines selected from the group consisting of CXCL4, CXCL9, CXCL10 and CXCL11, preferably CXCL9, as a prognostic marker in subjects with acute GVHD, particularly in subjects with high grade acute GVHD
-
公开(公告)号：EP3417291A1
公开(公告)日：2018-12-26
申请号：EP17705868.2
申请日：2017-02-16
IPC分类号： G01N33/564 , G01N33/68
摘要： The invention relates to a method for diagnosis of an autoimmune disease in a subject wherein, presence or absence of an anti-CXC chemokine receptor (CXCR) antibody is detected in a sample from the subject diagnosed, and wherein the presence of an anti-CXCR antibody is indicative of the disease. The invention further relates to the use of (auto)antibodies against the C-X-C chemokine receptor type 3 (CXCR3) as a prognostic marker in subjects with acute graft-versus-host disease (GVHD), particularly in subjects with high grade acute GVHD. The invention also relates to the use of C-X-C chemokines selected from the group consisting of CXCL4, CXCL9, CXCL10 and CXCL11, preferably CXCL9, as a prognostic marker in subjects with acute GVHD, particularly in subjects with high grade acute GVHD.
-
公开(公告)号：EP3417291B1
公开(公告)日：2020-11-18
申请号：EP17705868.2
申请日：2017-02-16
IPC分类号： G01N33/564 , G01N33/68
-
公开(公告)号：EP3304087B1
公开(公告)日：2020-11-04
申请号：EP16724428.4
申请日：2016-05-24
IPC分类号： G01N33/68 , G01N33/564
-
5.发明公开
公开(公告)号：EP3298408A1
公开(公告)日：2018-03-28
申请号：EP16724366.6
申请日：2016-05-17
申请人： Celltrend GmbH
IPC分类号： G01N33/564 , G01N33/68
CPC分类号： G01N33/564 , G01N33/6893 , G01N2800/226
摘要： The application relates to a method for diagnosis of an antiphospholipid syndrome (APS) in a subject, wherein presence or absence of an anti-protease-activated receptor 1 (PAR1) antibody is detected in a sample from the subject diagnosed, and wherein the presence of an anti-PAR1 antibody is indicative of the disease. Furthermore, it relates to the use of PAR1 for the diagnosis of APS, as well as to a method of removing anti-PAR1 antibodies from isolated blood of a subject upon detection of said anti-PAR1 antibodies in a sample of said patient.
-
6.发明公开DIAGNOSIS OF AN AUTOIMMUNE DISEASE USING DETECTION OF ANTIBODIES DIRECTED AGAINST C5A-RECEPTOR 审中-公开使用检测抗C5a受体的抗体诊断自身免疫性疾病
公开(公告)号：EP3213075A1
公开(公告)日：2017-09-06
申请号：EP15787610.3
申请日：2015-10-30
申请人： CellTrend GmbH
IPC分类号： G01N33/564
CPC分类号： G01N33/564 , G01N2333/70596 , G01N2333/726 , G01N2800/101 , G01N2800/104 , G01N2800/347
摘要： The application relates to a method for diagnosis of an autoimmune disease, comprising the step of determining the presence or absence of antibodies directed against CSa-receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against CSa-receptor is indicative of an autoimmune disease in said subject. Furthermore, the application relates to kits comprising C5a-receptor or an immunogenic fragment thereof and the use of CSa-receptor.
摘要翻译： 本申请涉及诊断自身免疫性疾病的方法，包括确定待诊断受试者的样品中针对C5a-受体的抗体的存在或不存在的步骤，其中针对C5a-受体的抗体的存在是 指示所述受试者中的自身免疫性疾病。 此外，本申请涉及包含C5a受体或其免疫原性片段的试剂盒以及C5a受体或其免疫原性片段用于诊断自身免疫性疾病的用途。
-
7.发明公开DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 有权癌的AUTO-抗该血管内皮细胞生长因子的检测（VEGF）诊断
公开(公告)号：EP3102946A1
公开(公告)日：2016-12-14
申请号：EP15702482.9
申请日：2015-02-03
申请人： CellTrend GmbH
IPC分类号： G01N33/564 , G01N33/574 , G01N33/74
CPC分类号： G01N33/57449 , C07K14/515 , C07K16/2863 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/76 , G01N33/564 , G01N33/74 , G01N2333/475 , G01N2800/52 , G01N2800/56 , G16H10/40 , G16H50/20 , G16H50/30
摘要： The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
-
8.发明授权VERFAHREN ZUR VORHERSAGE EINES TRANSPLANTATABSTOSSUNGSRISIKOS UND IMMUNOLOGISCHER TESTKIT 有权方法用于预测TRANSPLANTATABSTOSSUNGSRISIKOS及免疫检测试剂盒
公开(公告)号：EP1393076B1
公开(公告)日：2005-06-15
申请号：EP02738068.2
申请日：2002-05-13
申请人： Celltrend GmbH
IPC分类号： G01N33/564 , G01N33/566 , G01N33/68
CPC分类号： G01N33/564 , G01N2800/245 , Y10S435/975
摘要： The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention also relates to the use of the AT1 receptor or functionally analogous peptides or proteins therof in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in biological materials e.g. in body fluids or tissues.
-
公开(公告)号：EP3102943B1
公开(公告)日：2018-10-31
申请号：EP15702275.7
申请日：2015-02-03
申请人： CellTrend GmbH
IPC分类号： G01N33/564 , G01N33/574 , G01N33/74 , A61K39/395
CPC分类号： G01N33/57449 , A61K39/3955 , C07K14/71 , C07K16/2863 , C07K2317/24 , G01N33/564 , G01N33/74 , G01N2333/475
摘要： The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor receptor (VEGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
-
公开(公告)号：EP3102945B1
公开(公告)日：2018-10-17
申请号：EP15702481.1
申请日：2015-02-03
申请人： CellTrend GmbH
IPC分类号： G01N33/564 , G01N33/74 , G01N33/574
CPC分类号： G01N33/74 , G01N33/564 , G01N33/57449 , G01N2333/485 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (EGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.022 秒)
